BioAge Labs, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIOA Nasdaq 2836 bioagelabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioAge Labs, Inc.

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China - Feb 8th, 2026 11:07 pm
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential - Jan 29th, 2026 1:00 am
BioAge Announces Pricing of Upsized $115.0 Million Public Offering - Jan 21st, 2026 8:30 pm
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Continued Tariff Threats, Investors Await President Trump's Speech at Davos - Jan 21st, 2026 6:51 am
BioAge Announces Proposed Public Offering - Jan 20th, 2026 2:01 pm
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - Jan 20th, 2026 7:00 am
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio - Jan 12th, 2026 2:20 pm
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk - Jan 12th, 2026 7:00 am
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - Dec 13th, 2025 8:35 am
Sector Update: Health Care Stocks Softer in Afternoon Trading - Dec 4th, 2025 11:52 am
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - Dec 4th, 2025 8:30 am
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - Dec 4th, 2025 7:00 am
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - Nov 25th, 2025 2:30 pm
Recent uptick might appease BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners after losing 55% over the past year - Nov 23rd, 2025 5:14 am
BioAge Labs to Present at Jefferies Global Healthcare Conference in London - Nov 7th, 2025 7:00 am
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates - Nov 6th, 2025 2:45 pm
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy - Nov 5th, 2025 5:45 am
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? - Oct 29th, 2025 4:15 am
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? - Oct 26th, 2025 4:33 pm
Ventyx shares soar after study suggests cardiovascular benefits for experimental drug - Oct 23rd, 2025 5:36 am